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Abstract
Biomarkers in Alzheimer’s disease (AD) have the potential to allow early and
more accurate diagnosis, predict disease progression, stratify individuals and
track response to candidate therapies in drug trials. The first fluid biomarkers
reflecting aspects of AD neuropathology were identified in cerebrospinal
fluid (CSF) in the 1990s. Three CSF biomarkers (amyloid-β 1–42, total tau
and phospho-tau) have consistently been shown to have diagnostic utility and
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are incorporated into the new diagnostic criteria for AD. These markers have
also been shown in longitudinal studies to predict conversion of mild
cognitive impairment to AD. However, a key issue with the use of CSF
biomarkers as a screening test is the invasiveness of lumbar puncture. Over
the last 20 years there has been an active quest for blood biomarkers, which
could be easily acquired and tested repeatedly throughout the disease course.
One approach to identifying such markers is to attempt to measure candidates
that have already been identified in CSF. Until recently, this approach has
been limited by assay sensitivity, but newer platforms now allow single
molecule-level detection. Another approach is identification of candidates in
large multiplex panels that allow for multiple analytes to be quantified in
parallel. While both approaches show promise, to date no blood-based
biomarker or combination of biomarkers has sufficient predictive value to
have utility in clinical practice. In this review, an overview of promising
blood protein candidates is provided, and the challenges of validating and
converting these into practicable tests are discussed.
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Key Points
Many studies have identified candidates for blood biomarkers of Alzheimer’s
disease (AD) but replication has been problematic.
The two main candidates showing promise currently are plasma total tau and
serum neurofilament light chain.
New techniques such as multiplexing and use of more sensitive assays are likely
to expand and improve blood biomarker research.
1.  Introduction
The neuropathological signature of Alzheimer’s disease (AD) is neuronal loss
with deposition of amyloid-β (Aβ) in extracellular plaques and accumulation of
hyper-phosphorylated tau protein in intracellular neurofibrillary tangles.
Extrapolation from post-mortem studies suggests that in most cases these
proteins propagate through the brain in a reliable progression, which is reflected
in neuropathological staging systems for AD [ 1 ]. These studies showed that
early stage AD neuropathology exists in individuals who are asymptomatic,
paving the way for pre-symptomatic diagnosis and clinical trials aiming to
prevent cognitive decline. Given the obvious limitations of obtaining brain
tissue during life, there has been considerable interest in discovering disease-
specific biomarkers both in the symptomatic and pre-symptomatic phases.
Ideal biomarkers have different characteristics based on the information they
aim to give [ 1 ]. For example, an ideal diagnostic biomarker would reliably
reflect in vivo pathology with high sensitivity and specificity. A screening
biomarker would combine at least moderate sensitivity with high specificity and
low cost. Conversely, a marker of progression may be downstream of the initial
pathology but reliably track change over time. For all biomarkers, reliability,
cost, and ease of acquisition and processing are important considerations.
The currently available biomarkers for AD include structural imaging (e.g.
magnetic resonance imaging [MRI] and computed tomography), functional
imaging (e.g. 18-fluorodeoxyglucose positron emission tomography [PET]),
molecular imaging (e.g. Aβ and tau PET) and fluid biomarkers (from
cerebrospinal fluid [CSF], blood and urine). The focus of this review is fluid
biomarkers in AD.
2.  Cerebrospinal Fluid Biomarkers: Established
and Emerging
Studies have shown that low CSF Aβ42 [ 2 ], high CSF total tau (t-tau) [ 3 ] and
high CSF phospho-tau [ 4 ] in life are correlated with a clinical diagnosis of AD,
and also with severity of AD pathology post-mortem [ 5, 6 ]. Moreover, several
large multicentre studies have shown this pattern to predict which patients with
mild cognitive impairment (MCI) will progress to AD [ 7, 8, 9 ]. This implies
that the change in CSF biomarkers must occur during the preclinical stage of
AD. This CSF biomarker signature is now established in both the International
Working Group (IWG)-2 and National Institute on Aging (NIA) diagnostic
criteria for AD, in pre-symptomatic, prodromal (MCI), typical and atypical
forms of AD [ 3, 10, 11, 12, 13 ].
Newer CSF biomarkers that reflect other aspects of AD remain an active topic
of research. The post-synaptic degeneration biomarker neurogranin has been
identified in multiple cohorts as being able to differentiate AD from control
with an effect size (defined as fold change in the mean biomarker concentration
between AD and control groups) of 1.9 in a recent meta-analysis by Olsson et
al. [ 14 ], and to differentiate MCI patients who will progress to AD [effect size
1.5] [ 15 ]. Other studies have provided evidence that numerous other CSF
markers may be able to distinguish AD from controls, including heart fatty acid
binding protein [ 16 ], neuron-specific enolase [ 17 ], neurofilament light chain
(NFL) [ 18 ], YKL-40 [ 19 ] and visinin-like protein-1 [ 20 ], with effect sizes
ranging from 1.3 to 2.3. However, none is currently more diagnostically useful
than the established markers Aβ42 and tau, suggesting that the true utility of
these additional markers will come from understanding their relationship to the
underlying pathology, and in using them to ask more refined questions. For
example, a diagnostic marker is most useful when it can differentiate AD from
other dementias. This has been recently observed by Wellington et al. [ 21 ] for
neurogranin, which rises specifically in AD but not in other diseases such as
Lewy body dementia (LBD) and behavioural variant frontotemporal dementia
(FTD) which often are in the differential diagnosis of AD. Another more
specific function of a diagnostic biomarker would be to differentiate subtypes of
AD. Paterson et al. [ 22 ] have shown that the latter may be the case for CSF
NFL, which is higher in the CSF of patients in the frontal variant subgroup of
AD than in other ‘atypical’ variants of AD as defined by the IWG-2 criteria; this
represents a group that tends to have younger onset and more aggressive
disease.
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‘Traditional’ assay development has been on a single candidate molecule
approach, devising specific enzyme-linked immunosorbent assays (ELISAs) for
proteins thought to be relevant to the disease. This approach has its limitations:
it is slow and relies on a priori assumptions of the role of the candidate analyte
in disease pathogenesis. Thus, many groups have turned to employing
multiplexing approaches in CSF [ 23, 24 ]. A recent example is Heywood et al.’s
mass spectrometry-based targeted proteomics assay in CSF from two
independent cohorts[ 63 ] , I have been unable to assign the correct numbering to
this reference, which was inserted twice (once fully and once partially) as reference 63
and 64. Please reassign it as number 25, adjusting the numbering of the further
references below, including those in the table. AK.  which demonstrated 23
proteins (six of which were novel) that differentiate AD and LBD from controls.
Four proteins (two of which were novel) differentiated AD from both LBD and
controls. Many of these markers did not show a relationship with CSF Aβ42, t-
tau or phospho-tau, implying that their association with the pathology of AD
may be unrelated to amyloid plaques and tau neurofibrillary tangles.
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3.  Minimally Invasive Tests
While CSF biomarkers have proven utility, obtaining CSF remains a relatively
invasive procedure. Lumbar puncture is not without complications (the
commonest of which is headache) and it is relatively contraindicated in patients
with clotting disorders and those who are taking anticoagulant medication. It
requires a skilled operator and appropriate facilities to take, process and store
samples, which are sensitive to handling errors. This set of systems and
processes adds to the overall cost of the test. The optimal biomarker(s) would
therefore be obtained via a non-invasive, relatively cheap and easily repeatable
test. Blood, which is collected paired with CSF in most major fluid biomarker
research initiatives, provides this opportunity.
4.  Blood Biomarkers
4.1.  The Candidate Approach
Identification of peripheral biomarkers reflecting central nervous system (CNS)
dysfunction is challenging for many reasons. First, molecules from the brain
must cross the blood–brain barrier. Second, their concentration in blood is
likely to be much smaller than that in CSF, due to the much higher volume of
dilution in blood. Third, the high concentration of plasma proteins can be either
a sink for secreted proteins from the brain (due to binding or enzymatic
breakdown) or a source of similar or identical proteins. Taking the example of
plasma Aβ42, many of these factors come into play. Aβ42 is present at very low
concentrations in plasma, it is prone to plasma protein binding and may be
eliminated by enzyme activity. These factors may explain why plasma Aβ42
does not correlate well with the CSF profile [ 25, 26, 27, 28 ] and there are
mixed reports of inverse correlation [ 29 ] and of lack of correlation [ 30 ] of
plasma Aβ42 with amyloid PET. Further problems with plasma Aβ42 are its
susceptibility to technical factors such as aliquot volume and delay to freezing
samples [ 31 ].
To date, only one blood biomarker has been shown to distinguish AD from
control subjects across multiple patient populations. Plasma t-tau was shown in
a recent meta-analysis across six comparisons [ 32, 33 ] to have an effect size of
1.95 (95 % CI 1.12–3.38; n = 271 AD, 394 controls). Yet even within this meta-
analysis there was significant variation depending on the method used to
quantify t-tau. One of these studies showed a significant inverse effect [ 34 ] and
one showed no appreciable effect [ 35 ]—both used conventional ELISA
methods that were not optimised to measure the low concentrations of tau in the
blood. A more sensitive immunomagnetic reduction method was used in three
other comparisons derived from two studies by the same group [ 36, 37 ] and
showed effect sizes consistent with the results of the overall meta-analysis, but
these results, using this particular measurement technique, are in need of
independent replication. The final study [ 38 ] utilised a single molecular digital
array platform that is able to quantify t-tau at the single molecule level and
proved to have the highest sensitivity of the three methods [ 39 ]. This study
compared AD with MCI and control subjects from a Swedish cohort, showing
that while plasma t-tau differentiates AD from control, there is no significant
effect for MCI versus control. The former finding has been replicated in the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort and the Swedish
BioFINDER study [ 40 ] and the latter finding has been independently replicated
in a larger cohort from the Mayo Clinic Study of Aging [ 41 ], using the same
platform. While the difference in plasma t-tau levels between MCI and control
did not reach statistical significance, there was a significant inverse correlation
between plasma tau and cognitive performance (in the global, memory and
attention/executive function domains), as well as between plasma t-tau and
cortical thickness in an AD region of interest defined on MRI. A summary of
the studies published thus far is provided in Table 1 .
Table 1
Key blood biomarker studies in Alzheimer’s disease showing significant results using
the candidate approach
Study,
year Assay
Cohort
(n)
Summary of results (effect
size 95 % CI)
Total plasma tau
 Sparks et
al. 2012
[ 34 ]
ELISA
AD (49)
Control
(110)
Tau lower in AD (effect size
0.6–0.7)
 Chiu et
al. 2013
[ 36 ]
Immunomagnetic
reduction
2 AD
groups
(31 + 30)
Control
(107)
Tau higher in AD (effect size
2.3–9)
 Chiu et
al. 2014
[ 37 ]
Immunomagnetic
reduction
AD (10)
Control
(30)
Tau higher in AD (effect size
2.8–4.3)
 Zetterberg Single molecular digital AD (54) Tau higher in AD (effect size
et al. 2013
[ 38 ]
immunoarray Control
(25)
1.3–3)
 Dage et
al. 2016
[ 41 ]
Single molecular digital
immunoarray
MCSA
cohort:
MCI
(161)
Control
(378)
Tau in MCI was not
statistically significantly
higher than in controls but
after adjustment for age, sex,
education and APOE
genotype, higher tau was
associated with:
1. Worse performance in
tests of global cognition,
memory and attention; and
2. Reduced cortical thickness
in an AD signature region on
MRI
NFL, serum
 Bacioglu
et al. 2016
[ 47 ]
ELISA adapted to
electrochemiluminescent
platform
Control
(35)
MCI
(33)
AD (34)
IPD (32)
DLB
(20)
MSA
(17)
PSP (24)
CBS
(10)
Serum NFL higher in AD
(effect size ~3) but not
statistically significant for
MCI
Significant correlation
between cognitive
performance on MMSE and
CSF NFL or serum NFL in
AD
AD Alzheimer’s disease, CBS corticobasal syndrome, CI confidence interval,
CSF cerebrospinal fluid, DLB dementia with Lewy bodies, ELISA enzyme-linked
immunosorbent assay, IPD idiopathic Parkinson’s disease, MCI mild cognitive
impairment, MCSA Mayo Clinic Study of Aging, MMSE Mini-Mental State
Examination, MRI magnetic resonance imaging, MSA multisystem atrophy, NFL
neurofilament light chain, PSP progressive supranuclear palsy
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While plasma tau shows some promise, interpretation of the various studies is
not easy, given that plasma t-tau is known to vary widely even in healthy
individuals; and tau elevation is not specific to AD, as it is seen in many
diseases with rapid neuronal destruction (e.g. prion disease) as well as after
traumatic brain injury [ 42 ]. There is also a lack of correlation between CSF and
plasma t-tau within individuals [ 35 ]. Further studies in different cohorts are
needed to understand what plasma tau elevation means before it can be more
routinely used in research and certainly before any potential clinical translation.
Another recent advance in the blood biomarker domain is the discovery of the
relationship between serum NFL and the progression of neurodegenerative
diseases. NFL in CSF may discriminate FTD from other types of dementia [ 43 ]
and be an indicator of disease severity in FTD [ 44 ]. More recently, there have
been reports of serum NFL also reflecting disease severity in FTD [ 45, 46 ] and
correlating with the annualised frontal lobe atrophy rate in FTD [ 46 ]. In an
extensive body of work spanning mouse APP-PS1 (amyloid precursor protein–
presenilin 1) mutant models and human CSF and blood sampling, Bacioglu et
al. [ 47 ] showed that both CSF and serum NFL are raised in AD compared with
control patients. Serum NFL was highest in patients with tauopathies (with
effect sizes ~3 to 6) and moderately high in those with AD and atypical
parkinsonian syndromes (with effect sizes ~3), but was no different in those
with idiopathic Parkinson’s disease compared with controls, lending support to
the view that this may be a useful test in distinguishing idiopathic Parkinson’s
disease from atypical parkinsonism. Serum NFL broadly correlated with CSF
within individuals (a finding that has been corroborated by others for both
serum [ 48 ] and plasma [ 49 ]) and also correlated with Mini-Mental State
Examination scores. Treatment of the mouse APP-PS1 models with a β-
secretase-1 inhibitor, which reduces the generation of Aβ42 and the formation
of amyloid plaques, led to a reduction in both CSF and plasma NFL, which was
not observed in the untreated APP-PS1 mice. Taken together, these findings
raise the prospect of using blood NFL as a possible treatment response
biomarker in AD trials, as, unlike plasma t-tau, serum NFL seems to track the
CSF levels and the progression of disease. Notably, a statistically significant
elevation in serum NFL was not seen in MCI, but this may yet change as serum
NFL is measured in pre-symptomatic and mildly symptomatic subjects (such as
in the Dominantly Inherited Alzheimer’s Network cohort) with higher
sensitivity assays such as single molecular array. It will be interesting in such
cohorts to determine whether models that combine serum NFL levels with serial
MRI data could provide more predictive value for disease severity than using
either test alone.
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Any such efforts will need to adopt a standardised approach across centres to
allow for cross-validation, and there is now an international working group pre-
analytic processing guideline [ 50 ], which will continue to evolve as additional
research findings become available. The guideline refers to “controllable” and
“uncontrollable” variables. These match technical variables (in blood
collection/handling/storage) and patient factors (such as demographics,
genotype, co-morbidities and lifestyle factors), respectively. While the former
should be standardised, collecting information on the latter will allow for
stratification and interesting between-group comparisons that may ultimately
inform the application of a particular biomarker as a screening, diagnostic,
prognostic or therapeutic indicator.
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4.2.  Multiplexing
As has occurred in the CSF field, multiplexing approaches to plasma
proteomics have been employed by several investigators in an effort to define
groups of proteins that may inform pathways to the development and
progression of AD. A selection of some notable studies is provided in Table 2 .
The earliest of these studies, by Ray et al. [ 51 ] in 2007, used a sandwich
ELISA immunoassay platform and identified an 18-analyte panel of proteins
that segregated AD from controls. However, in an attempt at replication in
another cohort (ADNI), by using seven of the analytes that gave a combined
diagnostic accuracy of 90 % in the Ray et al. [ 51 ] study, 61 % diagnostic
accuracy was achieved, and the incorporation of a different 89-analyte panel
increased this to 70 % [ 52 ]. These results, however, have been difficult to
replicate [ 53, 54 ]. Doecke et al. [ 55 ] cross-validated panels of biomarkers
obtained from AIBL (Australian Imaging, Biomarkers and Lifestyle study)
against ADNI, and found just two biomarkers that had individual effect sizes
greater than 1.5 that were common to both cohorts: insulin-like growth factor
binding protein 2 and pancreatic polypeptide. However, when a multivariate
model using a panel of eight plasma biomarkers was added to the predictive
capacity of a model based on age, sex and APOE genotype, the biomarker panel
was only able to increase sensitivity and specificity from 77 to 83 %. This
emphasises the importance of assessing how much actual additional predictive
information is provided by these tests, as it ultimately relates to the cost-benefit
analyses that will determine their ability to translate into more general research
or clinical settings.
Table 2
Key blood biomarker studies in Alzheimer’s disease showing significant results using the
multiplexing approach. This represents a non-exhaustive list of relevant studies
Study,
year Assay Cohort (n) Markers
Summary of
results
AD (41)
Control (30)
3 proteins (APOE,
transthyretin and
Zhang et
al. 2004
[ 56 ]
LC + SDS-PAGE + MS
Cross-validation with WB
and ELISA
Study also
included
sera from
patients
with
insulin-
resistant
diabetes
mellitus and
congestive
heart failure
patients
In serum: 12
proteins
elevated in
AD; 1 protein
reduced in
AD
histidine-rich
glycoprotein) show
specific elevations
in AD but not in
other disease sera
1 protein shows
specific reduction
in AD: α-1 acid
glycoprotein
No statements of
diagnostic accuracy,
sensitivity or
specificity
Lopez et
al. 2005
[ 59 ]
AC + MS
AD (62)
MCI (33)
Control
(207)
In serum: 2
models
generated by
peptide
spectral
signatures
Sensitivity 83 %
and specificity 90–
96% achieved by
the 2 models;
contribution of
individual peptides
not analysed
Ray et al.
2007
[ 51 ]
Cytokine antibody
microarray; sandwich
ELISA
AD (85)
MCI (47)
Other
dementia
(11)
Other
neurological
disease (22)
Rheumatoid
arthritis
(16)
Control (79)
In plasma:
120 cell
signalling
proteins
probed; 18
proteins
identified
91 % accuracy in
predicting MCI
converting to AD,
100 % accuracy in
predicting MCI
converting to non-
AD dementia
Soares et
al. 2009
[ 52 ]
Sandwich ELISA
ADNI
cohort: AD
(61)
Control
(952)
In serum: 151
protein panel,
including 8
proteins from
Ray et al.
[ 51 ]
61 % accuracy in
classifying AD vs.
control; unable to
replicate results of
Ray et al. [
Doecke et
al. 2012
[ 55 ]
Multiple methods,
including:
multiplexed immunoassay
platform for a 151 protein
panel
ELISA for Aβ40 and
Aβ42
MS for metal ions and
protein panel
genotyping for APOE
statistical methods for
generating a predictive
model based on age, sex,
education level and APOE
genotype
AIBL
cohort:
AD (207)
Control
(754)
ADNI
cohort:
AD (112)
Control (58)
In plasma:
151 analytes
probed:
138 proteins
associated
with AD of
these, 8
markers were
chosen:
cortisol,
IGFBP2,
PPY, IL-17,
VCAM1,
VCAM2 β-2
microglobulin
EGFR and
IGFBP2 and PPY
each had individual
effect sizes >1.5;
these and several
other markers had
been replicated in
other studies
The 8 most
predictive markers,
which were flagged
by each of four
statistical methods,
were able to
increase the
sensitivity and
specificity of the
predictive model
based on age, sex,
CEA education and
APOE genotype
from 77 to 83 %
Hu et al.
2012
[ 61 ]
Multiplexed
immunoassay platform
for a 190 protein panel
APOE genotyping
Penn
cohort:
Control
(126)
MCI (16)
AD (88)
Other
dementias
(37)
 
WU cohort:
Control
(242)
CDR 0.5 or
very mild
dementia
(63)
CDR 1.0 or
mild
dementia
(28)
 
ADNI
cohort (both
clinical
diagnoses
and CSF-
driven
diagnoses
available):
Control (58)
MCI (396)
AD (112)
In plasma in
Penn and WU
cohorts:
17 candidate
proteins
identified in
univariate
analysis
across both
cohorts to be
associated
with clinical
MCI/AD; 5
replicated by
another study
in serum
6 of these
survived
multivariate
analysis and
correction for
age and sex
In fasting
plasma in
ADNI:
6 candidates
were
identified by
univariate
analysis
4 of these
showed
correlations
with disease
status defined
by CSF
2 of these
survived
multivariate
6 markers were
common to both
testing cohorts for
MCI/mild
dementia/AD: α-1-
antitrypsin, APOE,
CRP, N-terminal
pro B-type
natriuretic peptide,
osteopontin and
serum amyloid P.
Individual effect
sizes ranged from
0.8 to 1.1.
In the ADNI
validation cohort,
when disease status
was defined by a
CSF signature of
CSF Aβ 42
levels <193 pg/mL
and a CSF t-tau/Aβ
42 ratio >0.39, 4
markers were
identified: APOE,
BNP, CRP, and
pancreatic
polypeptide. The
latter 3 were
independent of
cholinesterase
inhibitor use
BNP and pancreatic
polypeptide showed
significant linear
correlation with the
APOE4 allele
number and the
CSF Aβ 42 level;
pancreatic
polypeptide also
showed significant
linear correlation
with the CSF t-
tau/Aβ 42 ratio
APOE, BNP and
CRP were therefore
common to all 3
cohorts.
The main
limitations of the
study included:
1. methodological
differences across
the three cohorts in
the sample
analysis and
correction for
age and sex
collection (fasting
vs. non-fasting)
2. the grouping of
MCI/mild
dementia/AD vs.
controls in the
analysis, resulting
in an inability to
comment on the
correlation between
these markers and
disease severity
3. small individual
effect sizes and low
contribution of the
plasma biomarkers
to explaining the
variance in the CSF
markers in the
ADNI cohort
Björkqvist
et al. 2012
[ 53 ]
Quantitative multiplex
ELISA
electrochemiluminescence
multiarray
AD (142)
Control
(174)
Other
dementias
(88)
In plasma:
EGF, PDGF-
BB and MIP-
1δ
3 markers able to
distinguish AD
from control but not
from other
dementias;
diagnostic precision
63 %
Trushina
et al. 2013
[ 57 ]
LC + MS
AD (15)
MCI (15)
Control (15)
342 plasma
and 351 CSF
metabolites
altered in AD
23 altered canonical
pathways in plasma
and 20 in CSF in
MCI vs. control
with a false
discovery rate of
<5 %
Sattlecker
et al. 2014
[ 58 ]
Aptamer-based
microarray
AD (331)
MCI (106)
Control
(211)
43 MCI
patients
converted to
AD within a
year
In plasma:
total of 355
proteins
associated
with at least 1
of the
outcome
measures; 13-
member
panel selected
20 proteins
associated
with
conversion of
MCI to AD
but none
passed
multiple
testing
corrections
Biomarker profiles
correlated with
different outcome
measures,
including:
region-specific
atrophy on MRI
(e.g. pancreatic
prohormone
correlated with left
hippocampal
volume)
rate of cognitive
decline (e.g.
clusterin)
13 protein panel
showed sensitivity
67 %, specificity
64 %, positive
predictive value
70 %
Untargeted
Mapstone
et al. 2014
[ 62 ]
LC + MS
screen:
Control
elderly (53)
MCI/mild
AD (53,
including
18
converters
over
2 years)
Targeted
panel
(separate
cohort):
Normal
elderly (20)
MCI/mild
AD (21,
including
10
converters
over
2 years)
In fasting
plasma: 10
plasma lipids
10 lipid panel able
to distinguish
converters from
normal controls
with diagnostic
precision 90 %;
sensitivity and
specificity of about
90 %
Able to distinguish
current AD from
controls with
precision of 77 %
Casanova
et al. 2016
[ 54 ]
Identical to Mapstone et
al. [ 62 ]
BLSA
cohort:
AD (93)
Control (99)
AGES-RS
cohort:
AD (100)
Control
(100)
In fasting
serum: 187
metabolites
probed
including 10
lipid panel
previously
identified by
Mapstone et
al. [ 62 ]
Larger-scale
attempt at
validating the 10
lipid panel from
Mapstone et al.
[ 62 ] in serum
samples collected
after overnight fast
BLSA cohort:
diagnostic precision
for distinguishing
MCI-to-AD
converters from
controls was 64 %,
sensitivity 51 %
and specificity 65%
AGES-RS cohort:
diagnostic precision
for distinguishing
MCI-to-AD
converters from
controls was 39 %,
sensitivity 47 %,
specificity 36 %
Across both
cohorts, able to
distinguish current
AD from controls
with precision of
48–58 %
Other metabolites
flagged in wider
screen as being
useful
discriminators in
BLSA cohort were
Other multiplexing techniques have used mass spectroscopy, preceded by either
liquid chromatography or differential matrix or surface adsorption to enrich
samples for proteins at low concentration. While this type of approach does not
rely on the availability of specific antibodies to the analytes of interest, it is this
very point that makes the data noisy. Zhang et al. [ 56 ] piloted this approach by
identifying four proteins in AD versus control sera, using mass spectroscopy,
which was then cross-validated using immunoassays (ELISA and Western blot).
not replicated in
AGES-RS cohort
Jaeger et
al. 2016
[ 60 ]
Antibody microarray
AD (47)
Control (52)
svPPA (92)
600 secreted
cell
signalling
proteins
probed
3 groups of proteins
identified that
discriminate AD
from control and
from svPPA:
‘complement’,
‘apoptosis’ and
‘growth
regulationregulation
of growth’,
including a new
TGFβ/GDP/BMP
pathway which was
then investigated in
post-mortem human
brain homogenates
and in murine
hippocampal
culture models
39 proteins
identified that are
over- or under-
expressed in both
AD and svPPA
Aβ amyloid-β, AC affinity chromatography, AD Alzheimer’s disease, ADNI Alzheimer’s
Disease Neuroimaging Initiative, AGES-RS Age, Gene/Environmental Susceptibility –
Reykjavik Study, AIBL Australian Imaging, Biomarkers and Lifestyle study, APOE
apolipoprotein E, BLSA Baltimore Longitudinal Study of Ageing, BNP brain natriuretic
peptide, CDR Clinical Disease Rating scale as per the NINCDS-ADRDA (National Institute
of Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and Related
Disorders Association) 1984 criteria for Alzheimer’s disease, CEA carcinoembryonic
antigen, CRP C-reactive protein, CSF cerebrospinal fluid, EGF epidermal growth factor,
EGFR epidermal growth factor receptor, ELISA enzyme-linked immunosorbent assay,
IGFBP2 insulin-like growth factor binding protein 2, IL-17 interleukin-17, LC liquid
chromatography, MCI mild cognitive impairment, MIP-1δ macrophage inflammatory
protein-1δ, MS mass spectrometry, PDGF-BB platelet-derived growth factor BB, Penn
University of Pennsylvania cohort, PPY pancreatic polypeptide, SDS-PAGE sodium dodecyl
sulphate polyacrylamide gel electrophoresis, svPPA semantic variant primary progressive
aphasia, TGFβ/GDF/BMP transforming growth factor-β/growth differentiation factor/bone
morphogenetic protein, t-tau total tau, VCAM vascular cell adhesion molecule, WB Western
blot, WU Washington University cohort
Similar methods have been employed to compare signatures of metabolites in
CSF and plasma of controls, MCI and AD patients [ 57 ]. A newer method is the
use of aptamer-based microarrays, which use oligonucleotides that function
with high specificity, almost like ‘chemical antibodies’, but are more thermally
stable and might therefore be more clinically translatable [58 ].
Multiplexing provides clear advantages by allowing large numbers of candidate
biomarkers to be screened, provided that these replicate well across cross-
sectional and longitudinal cohorts. Although to date replication has largely been
lacking, the primary ‘hits’ obtained so far have often segregated into classes of
proteins identified from other realms of biology, for example from the
‘inflammatory cascade’, ‘lipid metabolism’, ‘complement’ and other groups.
However, it is uncertain to what extent one can extrapolate the role of these
proteins from blood to a distant underlying pathology in the CNS. Data-driven
approaches also have other disadvantages. Firstly, to quote Lopez et al. [ 59 ],
“Given a sufficiently large pool of potential proteins and peptides, one is almost
certain to identify a pattern that discriminates between persons with and without
disease within any given data set”. This is the age-old problem of multivariate
analysis, which can be mitigated to some extent by statistical rigour, but
ultimately requires replication in independent cohorts. Secondly, biomarkers
may be able to answer more powerful questions if their relationship to
pathology, and indeed to factors such as healthy aging or other dementia
pathologies, is known. We can begin to derive such knowledge by integrating
diverse research tools such as genomics and transcriptomics with proteomics. A
recent example is the work of Jaeger et al. [ 60 ] who used an in-house immune
microarray to probe a library of 600 secreted signaling proteins in plasma from
AD patients, semantic dementia patients and healthy controls. They identified
protein clusters that map to ‘complement’, ‘apoptosis’ and ‘regulation of
growth’, many of which were hits on previous multiplex analyses, but a novel
pathway, the TGFβ/GDF/BMP (transforming growth factor-β/growth
differentiation factor/bone morphogenetic protein) cluster, was identified. The
potential relevance of this pathway was supported through the demonstration of
a large number of single nucleotide polymorphisms at the gene level in AD
patients, and correlation with lower GDF3 protein levels in post-mortem
cortical extracts from AD patients. Whilst replication in other cohorts and
validation using more conventional immunoassays such as ELISA will be
required, the identification of this pathway illustrates that an integrated
approach may prove to be a way of discovering new biomarkers and elucidating
their function, with the ultimate aim of identifying therapeutic targets.
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5.  Moving Forward
Despite the inherent problems in developing blood-based biomarkers that
accurately reflect brain biochemistry, ever more sensitive instruments and
unbiased methodologies to screen large numbers of proteins concurrently mean
that there is now a very real prospect of clinically useful blood-based
biomarkers for AD. Blood measures of tau and of NFL are currently leading
blood-based biomarker candidates; further work is required to understand what
role they may play as diagnostic, prognostic or outcome measures in AD.
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